Revvity Inc
Aperta
SettoreSettore sanitario
100.61 0.99
Panoramica
Variazione del prezzo dell'azione
24h
Minimo
99.09
Massimo
101.17
Entrata | -58M 41M |
|---|---|
Vendite | -61M 711M |
P/E Media del settore | 47.293 49.052 |
EPS | 1.06 |
Rendimento da dividendi | 0.27 |
Margine di Profitto | 5.726 |
Dipendenti | 11,000 |
EBITDA | -37M 181M |
Raccomandazioni | Acquista |
|---|---|
Previsioni per 12 mesi | +4.1% upside |
Rendimento da dividendi Media del settore | 0.27% 2.36% |
|---|---|
Utili prossimi | 27 lug 2026 |
Prossima data del Dividendo | 7 ago 2026 |
Prossima data del' Ex Dividendo | 17 lug 2026 |
Capitalizzazione di Mercato | 1.3B 11B |
|---|---|
Apertura precedente | 99.62 |
Chiusura precedente | 100.61 |
Notizie sul Sentiment di mercato
By Acuity
10%
90%
3 / 342 Classifica in Healthcare
Revvity Inc Grafico
Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.
Chi Siamo Revvity Inc
Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.